OBJECTIVES: To investigate the possibility of identifying DNA hypermethylation in the circulation of prostate cancer patients. METHODS: Plasma DNA samples were extracted from 36 prostate cancer patients and 27 benign prostate hyperplasia (BPH) cases. After extensive methylation-sensitive restriction enzyme digestion, the DNA samples were subjected to the real-time quantitative PCR amplification. Dissociation curve analysis was applied to determine if hypermethylation occurred in the promoter region flanking the GSTP1 gene, a well-documented epigenetic event among prostate cancer cells, in these plasma DNA samples. RESULTS: 11 of 36 prostate cancer patients showed positive peak pattern, indicating methylation changes occurred. Concordant data were obtained from the corresponding paraffin-embedded tissue samples available from the Tumor Bank. Twenty-five of the 27 BPH cases showed negative results, suggesting no methylation changes happened in the CpG islands in these cases. CONCLUSIONS: We have successfully identified prostate cancer genome hypermethylation in the peripheral circulation in prostate cancer patients with this protocol. This method can effectively distinguish BPH from prostate neoplasm. Although a larger number of samples are necessary to validate the capability of the protocol in practice, using plasma DNA sample is an ideal non-invasive approach for prostate neoplasm detection.
OBJECTIVES: To investigate the possibility of identifying DNA hypermethylation in the circulation of prostate cancerpatients. METHODS: Plasma DNA samples were extracted from 36 prostate cancerpatients and 27 benign prostate hyperplasia (BPH) cases. After extensive methylation-sensitive restriction enzyme digestion, the DNA samples were subjected to the real-time quantitative PCR amplification. Dissociation curve analysis was applied to determine if hypermethylation occurred in the promoter region flanking the GSTP1 gene, a well-documented epigenetic event among prostate cancer cells, in these plasma DNA samples. RESULTS: 11 of 36 prostate cancerpatients showed positive peak pattern, indicating methylation changes occurred. Concordant data were obtained from the corresponding paraffin-embedded tissue samples available from the Tumor Bank. Twenty-five of the 27 BPH cases showed negative results, suggesting no methylation changes happened in the CpG islands in these cases. CONCLUSIONS: We have successfully identified prostate cancer genome hypermethylation in the peripheral circulation in prostate cancerpatients with this protocol. This method can effectively distinguish BPH from prostate neoplasm. Although a larger number of samples are necessary to validate the capability of the protocol in practice, using plasma DNA sample is an ideal non-invasive approach for prostate neoplasm detection.
Authors: Jennifer A Rusiecki; Laura E Beane Freeman; Matthew R Bonner; Melannie Alexander; Ligong Chen; Gabriella Andreotti; Kathryn H Barry; Lee E Moore; Hyang-Min Byun; Freya Kamel; Michael Alavanja; Jane A Hoppin; Andrea Baccarelli Journal: Environ Mol Mutagen Date: 2016-12-20 Impact factor: 3.216
Authors: Patrick J Bastian; Ganesh S Palapattu; Srinivasan Yegnasubramanian; Craig G Rogers; Xiaohui Lin; Leslie A Mangold; Bruce Trock; Mario A Eisenberger; Alan W Partin; William G Nelson Journal: J Urol Date: 2008-02 Impact factor: 7.450
Authors: Lissette Delgado-Cruzata; Gregory W Hruby; Karina Gonzalez; James McKiernan; Mitchel C Benson; Regina M Santella; Jing Shen Journal: DNA Cell Biol Date: 2011-08-10 Impact factor: 3.550
Authors: Ailsa Sita-Lumsden; Claire E Fletcher; D Alwyn Dart; Greg N Brooke; Jonathan Waxman; Charlotte L Bevan Journal: Biomark Med Date: 2013-12 Impact factor: 2.851